Anti-p130 Cas (BCAR1) [8G4-E8] Antibody

This mouse IgG2a monoclonal antibody [8G4-E8] was generated against a GST fusion protein corresponding to residues 576-796 of rat p130 Cas and is reactive against human, mouse and rat p130 Cas.

Highlights

  • Reacts with human, mouse and rat p130 Cas
  • Suitable for Western Blot, Immunoprecipitation and Immunofluorescence applications

Breast cancer anti-estrogen resistance protein 1 (BCAR1, p130 Cas) is ubiquitously expressed adapter protein belonging to the Cas family. It can act as a docking protein containing multiple protein-protein interaction domains and used by many signalling partners.  Due to its ability to associate with many signaling partners, p130 Cas/BCAR1 has been shown to play a key role in cell adhesion, migration, apoptosis, hypoxia and mechanical forces. Over expression of  p130 Cas/BCAR1 has been identified in several cancer types including breast cancer.

From the laboratories of Amy H. Bouton, PhD and J. Thomas Parsons, PhD, University of Virginia.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
EG2003
Anti-p130 Cas (BCAR1) [8G4-E8] Antibody
100ug 4-6 weeks
Regular Price:$375.00
On Sale:
Specifications

Product Type: Antibody
Antigen: p130 Cas
Accession ID: P56945, NM 014567
Molecular Weight: 130 kDa
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: 8G4-E8
Reactivity: Human, mouse and rat
Immunogen: GST fusion protein corresponding to residues  576-796 of rat p130 Cas
Species Immunized: Mouse
Epitope: AA 576-796
Buffer: PBS, 0.05% (w/v) Sodium Azide
Tested Applications: WB, IF, IP
Storage: -20C
Shipped: Cold packs

Provider
From the laboratories of Amy H. Bouton, PhD and J. Thomas Parsons, PhD, University of Virginia.
References
  1. Bouton AH, Burnham MR. Detection of distinct pools of the adapter protein p130CAS using a panel of monoclonal antibodies. Hybridoma. 1997 Oct;16(5):403-11.

If you publish research with this product, please let us know so we can cite your paper.

Loading...